IPL 423088

Drug Profile

IPL 423088

Alternative Names: IPL 4088

Latest Information Update: 02 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Inflammatory bowel diseases

Most Recent Events

  • 02 Aug 2004 Discontinued - Preclinical for Asthma in Canada (PO)
  • 02 Aug 2004 Discontinued - Preclinical for Inflammatory bowel disease in Canada (PO)
  • 26 Feb 2003 No development reported - Preclinical for Asthma in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top